TLS Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

TLS Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Hold	30,956	–	–	5.49%	6
2026 Q1	$1.8M	Buy	30,956 +12,098	+64%	+$557K	4.27%	8
2025 Q4	$307K	Sell	18,858 -14,098	-43%	-$592K	0.81%	13
2025 Q3	$1.38M	Hold	32,956	–	–	4.02%	7
2025 Q2	$1.03M	Hold	32,956	–	–	3.22%	7
2025 Q1	$1.11M	Hold	32,956	–	–	2.5%	10
2024 Q4	$1.29M	Hold	32,956	–	–	2.95%	8
2024 Q3	$1.3M	Hold	32,956	–	–	2.74%	8
2024 Q2	$1.28M	Hold	32,956	–	–	3.22%	8
2024 Q1	$1.42M	Hold	32,956	–	–	3.3%	10
2023 Q4	$1.52M	Hold	32,956	–	–	5.04%	9
2023 Q3	$1.13M	Sell	32,956 -800	-2%	-$29.9K	4.56%	8
2023 Q2	$1.3M	Hold	33,756	–	–	5.58%	6
2023 Q1	$1.21M	Hold	33,756	–	–	6.21%	7
2022 Q4	$1.33M	Buy	+33,756	New	+$1.23M	6.56%	7

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

TLS Advisors's XENE Position: Q2 2026 in Review

TLS Advisors held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 30,956 shares worth $1.87M. The position accounts for 5.49% of the portfolio, ranked #6.

TLS Advisors first reported a position in XENE in Q4 2022 and has held it in 15 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

TLS Advisors held 30,956 shares of Xenon Pharmaceuticals worth $1.87M as of Q2 2026.
TLS Advisors left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 5.49% of TLS Advisors's portfolio in Q2 2026, its #6 holding.
TLS Advisors first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on TLS Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.